Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Biopharma Informatic LLC

Neither a doctor nor a teaching hospital

Research payments

$8,896,606

1,032 payments

Through program year 2025, Biopharma Informatic LLC is reported as receiving $8,896,606 in research payments, across 1,032 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $557,516 188
2024 Research $2,158,827 288
2023 Research $2,090,450 250
2022 Research $1,192,958 89
2021 Research $1,480,913 96
2020 Research $1,108,079 74
2019 Research $307,863 47

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vanda Pharmaceuticals Inc. $4,265,001 173 payments
  2. Genentech, Inc. $1,310,755 203 payments
  3. Horizon Therapeutics plc $591,104 13 payments
  4. Novartis Pharmaceuticals Corporation $474,948 14 payments
  5. Pfizer Inc. $416,939 123 payments
  6. GlaxoSmithKline, LLC. $332,645 88 payments
  7. AbbVie, Inc. $291,349 50 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $276,599 96 payments
  9. Sanofi Pasteur Inc. $179,450 32 payments
  10. Exact Sciences Corporation $155,217 20 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $2,237,856 69 payments
  2. Evaluating the Safety and Efficacy of Tradipitant VS. Placebo in Idiopathic and Diabetic Gastroparesis $2,027,145 104 payments
  3. Roche Cancer Screening Collection Study $1,306,009 199 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $284,879 2 payments
  5. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $231,336 34 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 $230,181 5 payments
  7. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 (The Empathy Trial) $172,132 5 payments
  8. A Lowinterventional Prospective Longitudinal Cohort Study to Collect Digital Functional Assessments and Evaluate Symptoms in Study Participants With Chronic Heart Failure $149,894 57 payments
  9. Infusion Duration Study to Assess Tolerability of Pegloticase Administered With A Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate $138,124 4 payments
  10. Informed Choice Intervention for Colorectal Cancer Screening - COMPASS $129,065 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record